What is 10x Genomics?
Headquartered in Pleasanton, California, 10x Genomics is an American biotechnology company specializing in the design and manufacturing of advanced gene sequencing technology. Its innovative solutions are widely adopted in scientific research, enabling breakthroughs in genomics and molecular biology. The company's technology plays a crucial role in advancing our understanding of biological systems, driving innovation across various life science disciplines.
How much funding has 10x Genomics raised?
10x Genomics has raised a total of $648M across 6 funding rounds:
Series A
$22.5M
Series B
$55.5M
Series C
$55M
Other Financing Round
$75M
Series D
$50M
Stock Offering
$390M
Series A (2013): $22.5M with participation from Venrock
Series B (2015): $55.5M led by Foresite Capital, Venrock, and Paladin Capital Group
Series C (2016): $55M supported by Foresite Capital, JS Capital Management LLC, SoftBank, Paladin Capital Group, Venrock, and Fidelity Management and Research Company
Other Financing Round (2018): $75M featuring Silicon Valley Bank
Series D (2018): $50M backed by Fidelity Investments, Meritech, SoftBank, Paladin Capital Group, and Wells Fargo
Stock Issuance/Offering (2019): $390M, investors not publicly disclosed
Key Investors in 10x Genomics
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data. The firm targets breakthrough opportunities at the intersection of technology and biotechnology, employing a data science-driven investment approach.
Paladin Capital Group
Paladin Capital Group operates as a global multi-stage investment firm specializing in venture capital and growth financing across diverse sectors. The firm deploys capital strategically to identify, support, and scale companies at various stages of development.
Venrock
Founded in 1969, Venrock is a venture capital firm known for its entrepreneurial support and strategic guidance, backing successful technology and healthcare ventures.
What's next for 10x Genomics?
The substantial enterprise-level funding and recent strategic investment indicate that 10x Genomics is in a robust growth phase, likely focused on scaling its operations, expanding its product portfolio, and further penetrating global markets. This capital infusion is expected to accelerate research and development initiatives, enhance manufacturing capabilities, and support strategic partnerships. The company's trajectory suggests a continued focus on innovation within the rapidly evolving field of genomics, positioning it for sustained leadership and impact.
See full 10x Genomics company page
